HealthcareServices

Global Myasthenia Gravis Treatment Market Performance Report: Global Trends 2026–2030

March 2, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the myasthenia gravis treatment market from 2026–2035 with trusted insights from The Business Research Company

What total market size is anticipated for the Myasthenia Gravis Treatment Market in 2030?

The myasthenia gravis treatment market size has witnessed strong expansion over recent years. It is anticipated to increase from $1.66 billion in 2025 to $1.79 billion in 2026, reflecting a compound annual growth rate (CAGR) of 7.8%. This historical growth can be linked to factors including the escalating prevalence of autoimmune disorders, the swift embrace of corticosteroids, the extensive clinical deployment of cholinesterase inhibitors, the proliferation of hospital-based MG treatment initiatives, and a heightened recognition of neuromuscular diseases.

The myasthenia gravis treatment market is anticipated to experience substantial expansion over the coming years. This market is projected to reach $2.43 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.0%. This projected growth during the forecast period is fueled by advancements in monoclonal antibody development, a heightened demand for minimally invasive surgical procedures, the expansion of specialized clinics, the increasing application of IVIG and cutting-edge immunotherapies, and improved diagnostic capabilities facilitated by AI-based tools. Key trends anticipated within this forecast timeframe encompass the growing embrace of immunosuppressive therapies, the expanded utilization of monoclonal antibodies for MG treatment, a rising preference for minimally invasive thymectomy procedures, increased demand for IVIG and plasmapheresis in critical situations, and the broadening of supportive and combination therapy strategies.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11980&type=smp

What Drivers Are Influencing Production Trends In The Myasthenia Gravis Treatment Market?

The increasing incidence of myasthenia gravis is projected to drive the expansion of the myasthenia gravis treatment market in the future. Myasthenia gravis is an autoimmune neuromuscular disorder characterized by fatigue and weakness in the skeletal muscles. Treating myasthenia gravis involves delivering healthcare services and patient care aimed at managing the condition. Consequently, the rising occurrence of myasthenia gravis is enhancing sales within the myasthenia gravis treatment market. For example, data from January 2024, provided by Myaware, a UK-based charity, indicates that out of an approximate United Kingdom population of 67,817,100, around 22,855 people are currently affected by myasthenia gravis, 204 by Lambert-Eaton myasthenic syndrome, and 2,103 by congenital myopathies. This demonstrates that the increased prevalence of myasthenia gravis is fueling the expansion of the myasthenia gravis treatment market.

Which Segments Are Gaining Traction In The Myasthenia Gravis Treatment Market?

The myasthenia gravis treatment market covered in this report is segmented –

1) By Treatment: Anticholinesterase Agents, Immunosuppressants, Monoclonal Antibodies, Plasmapheresis Or Intravenous Immunoglobulin (IVIg), Thymectomy Or Surgical Options, Other Treatments

2) By Route Of Administration: Oral, Intravenous, Subcutaneous

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Or E-commerce

4) By End User: Hospitals, Clinics, Other End-Users

Subsegments:

1) By Anticholinesterase Agents: Pyridostigmine, Neostigmine, Ambenonium

2) By Immunosuppressants: Corticosteroids, Azathioprine, Mycophenolate Mofetil, Cyclosporine, Tacrolimus

3) By Monoclonal Antibodies: Eculizumab, Rituximab

4) By Plasmapheresis Or Intravenous Immunoglobulin (IVIg): Plasma Exchange Therapy, IVIg Infusions

5) By Thymectomy Or Surgical Options: Transsternal Thymectomy, Minimally Invasive Thymectomy, Robot-Assisted Thymectomy

6) By Other Treatments: Symptomatic Therapy, Complement Inhibitors, Experimental Therapies

What Trends Are Expected To Impact The Competitive Landscape Of The Myasthenia Gravis Treatment Market?

Major companies in the myasthenia gravis treatment market are prioritizing the development of innovative products, such as self-administered complement C5 inhibitors, with the goal of enhancing treatment convenience, promoting patient autonomy, and reducing dependence on infusion-based care. These self-administered complement C5 inhibitors are targeted autoimmune therapies specifically formulated for subcutaneous use, enabling patients to manage excessive complement activation by independently administering their treatment at home rather than in clinical infusion settings. For example, in October 2023, UCB Pharma, a Belgium-based pharmaceutical company, announced that the US Food and Drug Administration (FDA) had approved Zilucoplan. This medication is prescribed for adults with generalized myasthenia gravis (gMG) who test positive for anti-acetylcholine receptor (AChR) antibodies. This approval provides a new management option for gMG, a condition defined by muscle weakness stemming from an autoimmune response. ZILBRYSQ stands out as a self-administered, once-daily subcutaneous complement C5 inhibitor, offering a convenient alternative to the traditional intravenous therapies that have long been the standard for treating gMG.

Who Are The Core Companies Influencing Trends In The Myasthenia Gravis Treatment Market?

Major companies operating in the myasthenia gravis treatment market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., Biogen Idec, CSL Limited, Chugai Pharmaceutical Co. Ltd., Grifols S.A, UCB Inc., Mitsubishi Tanabe Pharma Corp., Genentech Inc., Horizon Therapeutics plc, Amneal Pharmaceuticals Inc., Argenx SE, Immunovant Inc., Cabaletta Bio Inc., RemeGen Co. Ltd., Kedrion SpA

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/myasthenia-gravis-treatment-global-market-report

Which Region Is Projected To Lead The Myasthenia Gravis Treatment Market During The Forecast Period?

North America was the largest region in the myasthenia gravis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the myasthenia gravis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Myasthenia Gravis Treatment Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=11980&type=smp

Browse Through More Reports Similar to the Global Myasthenia Gravis Treatment Market 2026, By The Business Research Company

Musculoskeletal Disorder Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/musculoskeletal-disorder-drugs-global-market-report

Muscle Pain Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/muscle-pain-treatment-global-market-report

Muscle Tension Dysphonia Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/muscle-tension-dysphonia-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795